NDA 022100 · Cosette
Azor
Amlodipine Besylate, Olmesartan Medoxomil · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Oct 2, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Sep 26, 2007
Approved uses
2
Original approval plus efficacy supplements
Registered trials
656
178 Phase 3, 22 recruiting
FAERS reports
2,511
1,462 serious, 91 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue amlodipine besylate and olmesartan medoxomil as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus ( 5.1 , 8.1 ). WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue amlodipine besylate and olmesartan medoxomil as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ).
What it is approved for
From the label in effect Apr 28, 2026.
Amlodipine besylate and olmesartan medoxomil is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine besylate and olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased...
Mechanism: Amlodipine besylate and olmesartan medoxomil is a combination of two antihypertensive drugs: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, olmesartan medoxomil. The amlodipine component of amlodipine besylate and olmesartan medoxomil inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, and the olmesartan medoxomil component of amlodipine besylate and olmesartan medoxomil blocks the vasoconstrictor effects of angiotensin II. Amlodipine ....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 11, 2009 Supplement 2 · Efficacy LabelLetter
- Sep 26, 2007 Original approval · Type 4 - New Combination OrphanLetterReviewLabel
4 products under this application
- AZOR · AMLODIPINE BESYLATE EQ 5MG BASE; OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB
- AZOR · AMLODIPINE BESYLATE EQ 10MG BASE; OLMESARTAN MEDOXOMIL 20MG · TABLET, ORAL · Prescription · TE AB
- AZOR · AMLODIPINE BESYLATE EQ 5MG BASE; OLMESARTAN MEDOXOMIL 20MG · TABLET, ORAL · Prescription · TE AB
- AZOR · AMLODIPINE BESYLATE EQ 10MG BASE; OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.
- China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)Pivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974138 · 32,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2030
Drug: Amlodipine besylate; Amlodipine besylate and folic acid and 2 more · For: Hypertension; MTHFR 677 CC or CT Genotype; Elevated Plasma Homocysteine (Hcy≥10µmol/L) and 1 more
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT GenotypePivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974151 · 24,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2029
Drug: Amlodipine besylate; Amlodipine besylate And Folic Acid and 4 more · For: Hypertension; MTHFR 677 TT Genotype
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential HypertensionPivotal-lookingCompleted
Oslo University HospitalAcademic, hospital or other
NCT06395194 · 15,313 participants · Start Sep 27, 1997 · Primary completion Sep 5, 2003
Drug: Cardiac outcomes on treatment with valsartan; Cardiac outcomes on treatment with amlodipine · For: Essential Hypertension
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVDPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT05169021 · 15,000 participants (planned) · Start Dec 31, 2021 · Primary completion Dec 31, 2024
Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy and 2 more · For: Cerebral Small Vessel Diseases; Stroke
Sites: Beijing, China
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- sprue-like enteropathy327
- gastrooesophageal reflux disease210
- diarrhoea183
- dizziness180
- acute kidney injury170
- weight decreased166
- drug ineffective147
- nausea138
- haemorrhoids133
- chronic kidney disease126
- constipation116
- fatigue111
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2008 | 36 |
| 2009 | 101 |
| 2010 | 164 |
| 2011 | 176 |
| 2012 | 205 |
| 2013 | 117 |
| 2014 | 113 |
| 2015 | 379 |
| 2016 | 333 |
| 2017 | 239 |
| 2018 | 287 |
| 2019 | 134 |
| 2020 | 72 |
| 2021 | 42 |
| 2022 | 21 |
| 2023 | 22 |
| 2024 | 22 |
| 2025 | 27 |
| 2026 | 19 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Azor (Amlodipine Bes/Olmesartan Med)
2024 spending
$2.9M
Beneficiaries
720
3,507 claims
Per beneficiary
$3,986
$13.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,911,912 |
| 2021 | $4,352,589 |
| 2022 | $3,803,803 |
| 2023 | $3,345,694 |
| 2024 | $2,869,756 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H · Clin Cardiol 2023 · Systematic Review, Network Meta-Analysis
- Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.
Yin J, Mei Z, Shi S, et al. · Arch Gynecol Obstet 2022 · Meta-Analysis, Systematic Review
- Amlodipine pharmacokinetics in healthy volunteers.
Williams DM, Cubeddu LX · J Clin Pharmacol 1988 · Clinical Trial, Randomized Controlled Trial
- Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Jin X, Kim MH, Han KH, et al. · J Clin Hypertens (Greenwich) 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Amlodipine reduces blood pressure during dynamic resistance exercise in hypertensive patients.
Souza DR, Gomides RS, Costa LA, et al. · Scand J Med Sci Sports 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension.
Fowler G, Webster J, Lyons D, et al. · Br J Clin Pharmacol 1993 · Clinical Trial, Comparative Study
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.